
    
      Study ID-069A302 will continue at each site until lucerastat is commercially available in the
      respective country or until all subjects have reached either Month 24 (for subjects not
      participating in Stage 2) or Month 48 (for subjects participating in Stage 2), whichever is
      earliest.
    
  